Sivik Global Healthcare’s Teva Pharmaceuticals TEVA Stock Holding History

Sivik Global Healthcare’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-170,000	Closed	-$3.06M	–	46
2024 Q3	$3.06M	Sell	170,000 -30,000	-15%	-$525K	1.3%	31
2024 Q2	$3.25M	Buy	200,000 +25,000	+14%	+$385K	1.17%	32
2024 Q1	$2.47M	Buy	+175,000	New	+$2.21M	0.58%	44
2020 Q3	–	Sell	-275,000	Closed	-$3.39M	–	57
2020 Q2	$3.39M	Buy	+275,000	New	+$3.11M	1.12%	40
2019 Q2	–	Sell	-215,000	Closed	-$3.37M	–	69
2019 Q1	$3.37M	Buy	215,000 +30,000	+16%	+$529K	1.24%	39
2018 Q4	$2.85M	Sell	185,000 -15,000	-8%	-$308K	1.54%	31
2018 Q3	$4.31M	Sell	200,000 -85,000	-30%	-$1.97M	1.54%	32
2018 Q2	$6.93M	Sell	285,000 -70,000	-20%	-$1.43M	2.67%	8
2018 Q1	$6.07M	Buy	355,000 +80,000	+29%	+$1.56M	2.83%	10
2017 Q4	$5.21M	Buy	275,000 +175,000	+175%	+$2.63M	1.93%	20
2017 Q3	$1.76M	Buy	+100,000	New	+$2.25M	0.6%	61
2017 Q2	–	Sell	-50,000	Closed	-$1.6M	–	72
2017 Q1	$1.6M	Buy	+50,000	New	+$1.71M	0.75%	49
2016 Q2	–	Sell	-46,000	Closed	-$2.46M	–	64
2016 Q1	$2.46M	Sell	46,000 -45,000	-49%	-$2.64M	1.09%	38
2015 Q4	$5.97M	Buy	91,000 +11,600	+15%	+$717K	2.84%	5
2015 Q3	$4.48M	Sell	79,400 -10,000	-11%	-$648K	2.17%	19
2015 Q2	$5.28M	Buy	89,400 +9,400	+12%	+$580K	1.83%	18
2015 Q1	$4.98M	Buy	80,000 +20,700	+35%	+$1.2M	1.7%	21
2014 Q4	$3.41M	Buy	59,300 +4,300	+8%	+$240K	1.38%	32
2014 Q3	$2.96M	Hold	55,000	–	–	1.34%	37
2014 Q2	$2.88M	Sell	55,000 -14,350	-21%	-$733K	1.46%	30
2014 Q1	$3.66M	Buy	69,350 +9,350	+16%	+$432K	2.29%	8
2013 Q4	$2.4M	Buy	+60,000	New	+$2.36M	1.71%	30

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sivik Global Healthcare's TEVA Position: Q4 2024 in Review

Sivik Global Healthcare sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 170,000 shares — an estimated $3.06M sold.

Sivik Global Healthcare first reported a position in TEVA in Q4 2013 and held it in 22 quarters. The position peaked at $6.93M in Q2 2018. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

Sivik Global Healthcare reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Sivik Global Healthcare sold 170,000 Teva Pharmaceuticals shares in Q4 2024, an estimated $3.06M.
Sivik Global Healthcare first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 22 quarters.
Sivik Global Healthcare's Teva Pharmaceuticals position peaked at $6.93M in Q2 2018.
584 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Sivik Global Healthcare's 13F filing for Q4 2024, filed 23 Jan 2025.